In 2014, leading domestic generic pharmaceutical companies accelerated "counter attack"

At the beginning of this year, the news of Pfizer's divestiture of its generic pharmaceutical business was once again rampant According to foreign media, three pharmaceutical companies have expressed their interest in accepting the offer, but Pfizer did not formally respond Analysts believe that the business unit's sales in the first nine months of 2013 exceeded US $7 billion, which is still Pfizer's major profit maker and is not expected to change hands in the first quarter In fact, as early as 2013, Pfizer announced that it would examine the finance and marketing of its branded drugs and generic businesses separately to prepare for the sale of generic businesses in the next few years In July 2013, Pfizer announced plans to split its business into three divisions, including two for the sale of patented branded drugs and one for the sale of generic drugs It's just the same Paul Pizarro, CEO of atvis, the world's third largest generic pharmaceutical company, recently announced that the company will withdraw from the Chinese market completely because of the difficult market environment for the company to carry out business At present, the company has sold one business in China and is negotiating to sell another business In response, the Chinese side of atvez said that the company is still in normal operation and has not received the group's internal notice on "leaving China" According to industry insiders, the main reason for atvis's exit from China is its poor performance, which has little to do with the operating environment of the Chinese market It is understood that the business situation of other generic pharmaceutical companies in China is also very bleak For example, Suntech, a giant of generic drugs under Novartis, is the leader of foreign generic drugs Although its performance growth rate in the past two years is relatively fast, it still lags far behind its target of 10 billion sales AstraZeneca also announced in May 2013 that it would adjust its business strategy in China and suspend investment in the brand generic pharmaceutical market In fact, in recent years, with the implementation of the new GMP and the accelerated promotion of drug consistency evaluation, some foreign generic drugs and local generic drugs compete fiercely, and some foreign generic drug companies have to "survive by retreating" According to the data, in the five years from January 1, 2012 to December 31, 2016, there will be as many as 631 patent drugs with a total value of 225 billion US dollars expiring in the world Among them, from 2012 to 2015 alone, more than 100 drug patents expire every year, and the market space of generic drugs is further expanded The industry expects that with more and more foreign generic drugs leaving China, opportunities for domestic generic drug leaders such as Hengrui pharmaceutical, Laimei pharmaceutical, Haizheng pharmaceutical and Changshan pharmaceutical will begin to emerge Changshan Pharmaceutical Co., Ltd., Hengrui Pharmaceutical Co., Ltd., Laimei Pharmaceutical Co., Ltd and other companies will be approved for listing in 2014 to accelerate market share It is reported that in 2012, the global sales of sildenafil reached US $2.05 billion Pfizer's patent for indication of the drug expired in mid-2014 The generic drug sildenafil of Changshan pharmaceutical industry is expected to be launched in August September 2014 Although sildenafil is likely to reduce its price along with the listing of many imitated varieties, Changshan Pharmaceutical Co., Ltd., as one of the first listed enterprises, is still expected to obtain a large market share According to the analysis of securities researchers, this variety will become one of the important profit sources of the company in the next 3-5 years Esomeprazole, approved by Laimei pharmaceutical in September 2013, is also expected to be available in 2014 The head of the company previously disclosed to this newspaper that esomeprazole is expected to be officially listed in the first half of 2014 and start to generate benefits It is worth mentioning that the original patent of esomeprazole pharmaceutical factory expired in May 2014, and the first approved Laimei pharmaceutical industry will seize the opportunity Hengrui pharmaceutical has accumulated a number of reserve products in the research and development of generic drugs around tumor, contrast agent, cardio cerebrovascular, endocrine, nutritional medicine and other fields It is expected to enter the intensive harvest period in 2014, and it is expected to obtain 3-5 potential large varieties of generic drugs every year in the future It is worth mentioning that the global sales of capecitabine approved by Hengrui pharmaceutical and Qilu pharmaceutical reached US $1.6 billion in 2012, and the securities companies expect that capecitabine of Hengrui pharmaceutical is expected to become the key product of the company's tumor business promotion in 2014 Key words: in 2014, China's leading generic drug companies bucked the trend Next: Indian pharmaceutical companies approved 154 generic drugs by FDA in 2013 Last: Watson biological "intravenous immunoglobulin (pH4)" drug clinical research registration application was accepted [new drug express search] [addfav ('add to collection ');] [tell friends] [print this article ][close window] relevant reports • perspective of the domestic anti-tumor drug market from 2005 to 2014 • global market of psoriasis drugs in 2014 • top 20 global generic drug companies in 2014 • marginalization of traditional Chinese medicine approval; 501 approved new Chinese medicines in 2014 only account for the proportion of the total sales of Veterans' drugs in 2014 CFDA released the 2014 national drug abuse monitoring annual report The drugs that obtained the FDA breakthrough treatment qualification from June 2014 to June 2015 The ranking of R & D expenses of 190 listed pharmaceutical companies in China from 2012 to 2014 Gen: 20 biological companies that invested the most in R & D in 2014 The review of 25 best-selling drugs in the world in 2014 0 [see all] related comments